I am not criticizing the study. I am highlighting that the conclusion that the paper arrives at i the correct one: That it warrants large scale studies.
This work is a prime candidate for being misrepresented as showing that this stem cell treatment is effective for age related health issues.
There are 30 participants in the phase 2 trial. There are two treatment groups (100M and 200M) with different dose and one placebo group. Each group has 10 participants.
None of the treatment groups showed adverse effects.
There is a difference between asking "Are there any adverse effects?" and "are there positive effects for parameter 1 to n"? If you ask the second kind of question and do not correct for multiple hypothesis testing, you will make many errors.
The small dose treatment group (100M) showed improvement in many parameters vs placebo, whereas the other (200M) showed improvement in fewer parameters vs placebo. Since no corrections where made for testing, this only tell us that there where no statistically significant adverse effects.
As I noted initially, I think it is interesting. Once we have seen the results of a couple of large studies, we can talk about the effects of this treatment.
Thank you for your reply, in particular for the specific issue with the results. I quoted the article to show that the researchers seem to believe that the trial results are more promising than a formal analysis would suggest. I agree that further studies are required.
This work is a prime candidate for being misrepresented as showing that this stem cell treatment is effective for age related health issues.
There are 30 participants in the phase 2 trial. There are two treatment groups (100M and 200M) with different dose and one placebo group. Each group has 10 participants.
None of the treatment groups showed adverse effects.
There is a difference between asking "Are there any adverse effects?" and "are there positive effects for parameter 1 to n"? If you ask the second kind of question and do not correct for multiple hypothesis testing, you will make many errors.
The small dose treatment group (100M) showed improvement in many parameters vs placebo, whereas the other (200M) showed improvement in fewer parameters vs placebo. Since no corrections where made for testing, this only tell us that there where no statistically significant adverse effects.
As I noted initially, I think it is interesting. Once we have seen the results of a couple of large studies, we can talk about the effects of this treatment.